ALK and non-small cell lung carcinoma: In a phase I/II study on 46 individuals diagnosed with ALK-rearranged untreated NSCLC, stable disease was reported for at least 6.5 months for seven subjects; two patients showed a complete response, and 41 patients responded partially to treatment [27].